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One of the distinguishing features of multiple myeloma (MM) is the proliferation of a clonal 
plasma cell population in the bone marrow (BM).  It is of particular interest that the tumor 
plasma cells appear to be restricted to the microenvironment of the BM and are rarely detected 
in the peripheral system, yet the disease is found widely disseminated throughout the axial skeleton. 
Furthermore, isolation of MM tumor cell lines has proven to be quite problematic due to their 
slow growth rate.  These observations have instigated the search for earlier cells in the B cell 
lineage that are clonally related to the plasma cell tumor and that may represent the growth 
fraction of the tumor. We used allele-specific oligonucleotides (ASO) derived from the third 
complementarity determining region of the rearranged tumor immunoglobulin heavy chain gene 
to detect isotypes clonally related to the plasma cell tumor. By reverse transcribing RNA from 
the BM with a panel of CH primers (/~, 8, o~, and 30, followed by ASO-polymerase chain reaction 
amplification, we demonstrate the existence of preswitch isotype species that are clonally related 
to the myeloma tumor. Furthermore, we show that separation  of the BM cells into CD45 + 
and CD38 § cell populations results in a lineage-specific expression of the donally related RNA 
molecules, with the C/~ and C8 in the CD45 §  and C3~ in the CD38 § population. Interestingly, 
clonally related Co~ transcripts are also derived from the CD45 + fraction.  These results confirm 
the presence of B cell populations clonally related to the plasma cell tumor and are consistent 
with models that propose the existence of myeloma precursors. 
M 
ultiple myleoma is characterized by the clonal expansion 
. of the plasma cell compartment in the bone marrow 
(BM) 1 and is further distinguished by the production of a 
monoclonal Ig, as determined by idiotypic determinants and 
Ig gene rearrangements. A number of reports have suggested 
that various populations of B cells are clonally related to the 
plasma cell malignancy (1-14). Antiidiotypic antibodies gener- 
ated to the myeloma monoclonal protein have been shown 
to crossreact with B cells displaying different isotypes (1-4). 
Furthermore, coexpression of early B cell lineage markers and 
plasma cell markers have been observed on the malignant popu- 
lation (10-14).  The implication from these findings is that 
various phenotypes of a common B lineage may result from 
an oncogenic process affecting the B cell early in differentia- 
tion. Indeed, differentiation from Id + B cells to plasma cells 
1 Abbreviations used in this paper: ASO, allde-specific oligonucleotide; BM, 
bone marrow; MM, multiple myeloma;  RT, reverse transcription. 
in culture using cytokines (8), or phorbol ester induction (9), 
has been reported. However, there is dearly disagreement con- 
cerning the evidence that concludes there are early-B pro- 
genitors that are transformed and subsequently differentiate 
to the clonal plasma cell tumor. While cells containing Ig# 
protein that appear to be idiotypically identical to the my- 
eloma protein have been observed, these may be normal poly- 
clonal B cells bearing crossreactive Ids (15). Moreover,  ex- 
pression of multilineage markers, common in the myeloma 
plasma cell, has been observed on normal BM plasma cells (16). 
If B cells at various stages of differentiation are clonally 
related, it would be expected that they share common Ig gene 
rearrangements. Detection of clonal Ig gene rearrangements 
in mononuclear cells from blood and cultured precursor cells 
has been inconsistent (5-7, 17-19).  In part this may be due 
to limits in blot hybridization sensitivities. 
We (20,  21) and others (22-25)  have shown that PCR 
amplification of the Ig heavy chain gene junctional regions 
can provide very specific characterization of neoplastic B cell 
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sequence is clonally unique due to novel combinations of the 
V-D-J gene segments, random nucleotide deletions and in- 
sertions, and somatic mutations. We have used consensus oli- 
gonucleotide primers to amplify CDR3 of rearranged heavy 
chain alleles from lymphoid tumor samples (20,  21). From 
the sequence of the amplified product, allele-specific primers 
can be synthesized and used to detect the tumor-specific al- 
lele. Because this approach is specific for the tumor Ig heavy 
chain allele, it can provide a unique and useful tool to iden- 
tify clonally related populations of cells. In this study we have 
generated allele-specific oligonucleotide (ASO) primers from 
the predominant tumor population in the marrow of patients 
with IgG or IgA myeloma. RNA was isolated from their 
marrow, reverse transcribed with/~, ~, %  and oe constant 
region primers, and the cDNA was amplified using the ASO. 
Based on the PCR products and their sequence, we confirm 
the presence of B cells at different stages of development that 
are clonally related to the malignant population. Sorting of 
the BM sample into CD38 +/45-  or CD38-/45 + popula- 
tions, followed by reverse transcription (RT)-PCR of these 
populations with % oe, t5, and/z, demonstrates that the clone- 
specific transcripts are being generated by different cell com- 
partments. Moreover, sequence comparisons between early 
stage (#-/~-expressing)  clones and the clonaUy related, but 
more differentiated (3'- or (x-expressing),  clones showed se- 
quence stability (i.e., lack of accumulating somatic mutations) 
in the junctional region. 
Materials and Methods 
Multiple Myeloma (MM) Patient Samples.  Approximately 20  x 
106 frozen BM cells from patients with MM were received from 
the Mayo Clinic in RPMI containing 10% DMSO and 20% FCS. 
The samples were washed twice in lx PBS to remove  DMSO and 
then split in half. DNA was prepared from one half of the sample 
by standard protocol (26) and then resuspended in 200/~1 TE (10 
mM Tris, i mM EDTA), pH 7.0. Total cellular RNA was prepared 
from the other half of the sample as described by Chomczynski 
and Sacchi (27). 
V~ Family-specific Amplification of Rearranged Ig Heavy Chain 
Genes in Myetoma BM DNA.  PCR was performed essentially  as 
described by Saki et al. (28), using a J, consensus primer (20) or 
J4-specific primer, along with primers specific to the six V. gene 
families (29). For family-specific  PCR of each sample, seven 50-#1 
reactions were amplified  that contained  the following:  0.5/zg DNA, 
15 pmol of the J. or J4 primer, 15 pmol of a V. family primer, 
1.25 U  of Thermus flavus  polymerase (Epicentre Technologies, 
Madison, WI), 200/xmol/liter of each dNTP, 50 mmol/liter Tris- 
HCI,  pH 8.4, 20 mmol/liter NH4SO3, 1.2 mmol/liter MgCI~. 
The parameters for thermocycling were: 5-rain denaturation at 
95~  followed by 35 cycles of: 30-s denaturation at 94~  30-s 
annealing at 60~  and 45-s extension at 73~  and finally a 10- 
rain extension  at 73~  Negative  controls  of  normal peripheral  blood 
DNA and no template were run with each set of amplifications. 
PCR products were separated on a 6% polyacrylamide gel and 
visualized  by UV light after staining with ethidium bromide. Am- 
plification of sample M45 was only successful when amplifying 
with the J4 oligonucleotide paired with the V. family oligonu- 
cleotides, but not when using the JH oligonucleotide. Subsequent 
sequencing of the amplified  product showed  a deletion  encompassing 
the 5' region of the J. gene recognized by the 3' portion of the 
J. consensus oligonucleotide (see Fig. 3), thereby leading to the 
inability of J. to amplify this sample. 
DNA Sequence of Amplified Products.  Amplified  products were 
isolated as previously described (20). The sample was desalted on 
Ultra-free-MC 100,000 NMWL filters (Millipore, Bedford, MA). 
DNA sequencing was performed as previously described (20) or 
using the fmol sequencing kit (Promega Biotec, Madison, WI) as 
per supplier's protocol with the following alteration. Sequencing 
reactions containing the sequencing  buffer,  end-labeled  primer, tem- 
plate, and polymerase  were subjected to a 5-min denaturation step 
at 95~  followed by a snap-cool annealing of the primer to the 
template by placing in an ice-bath 10 min before distribution into 
termination mixes. Analysis of the sequencing reactions was per- 
formed as previously described (20). 
RT of Myeloma BM RNA  Using Constant Region Primers.  RT 
of RNA using constant region primers (Table 1) was performed 
in 20-#1 reactions containing: 3-5/ig RNA, 500 #tool/liter of 
each dNTP,  10 pmol of the constant region primer, 200 U  of 
Moloney murine  leukemia virus (MMLV)-RT (GIBCO  BRL, 
Gaithersburg, MD), 20 U RNasin (Promega  Biotec), 50 retool/liter 
KC1, 20  mmol/liter  Tris-HC1, pH  8.4, and  2.5  mmol/liter 
MgC12. The RNA and components minus the  enzymes were 
heated to 95~  for 3 min and then placed on an ice-bath for 10 
min. Next, the enzymes were added and the reaction was cycled 
under the following conditions: 10 rain at 25~  60-min extension 
of cDNA at 42~  and a 7-min enzyme inactivation at 95~ 
Allele-specific  Amplifications ofcDNA.  ASOs  were designed  from 
sequence information  and the primer position was maintained  within 
the CDR3 to obtain the highest specificity  (see Fig. 3). First-round 
amplification of the eDNA was carried out in 50-#1 reactions that 
contained: amplification  reaction buffer as described  above, but in- 
cluded one-fourth of the RT reaction, 15 pmol of constant region 
primer (CHA) paired with 15 pmol of a family-specific  V. primer 
for 30 cycles  of: 30-s denaturation at 94~  30-s annealing at 62~ 
and 45-s extension at 73~  with a final 10-min extension at 730C. 
The second-round amplification  was carried out in 50-/~1 reactions 
and contained: 5 #1 of the first-round amplification, 15 pmol of 
ASO primer, 15 pmol of an internal constant region primer (CHB), 
and the buffer conditions as described above. The reaction was cy- 
cled for 35 cycles under the above conditions with the annealing 
temperature ranging from 60 to 66~  depending on the melting 
temperature (Tin) of the ASO. Amplified products were separated 
on 8% polyacrylamide  gel and visualized  by UV light after ethidium 
bromide staining. 
FAGS  |  Sorting of MM BM Cells into CD38 + and CD45 § Popu- 
lations.  Frozen  BM from patients with MM were thawed and 
diluted into RPMI 1640. These samples were then centrifuged at 
1,800 rpm for 5 rain, aspirated, and finally resuspended in 4 ml 
of media. This wash was repeated twice to get rid of DMSO and 
cellular debris. The cells were resuspended after the final wash and 
cell counts were performed. 2  x  106 cells were aliquoted to each 
tube for staining with antibody. The antibodies used were FITC- 
conjugated CD45 and PE-conjugated CD38 (Becton Dickinson 
& Co., Mountain View, CA). The cells were incubated with the 
antibodies for 30 rain at 4~  then washed twice with RPMI and 
resuspended in 1 ml of media. Sorts were performed on either a 
FACStar  |  or a FacsVantage  |  flow cytometer (Becton Dickinson 
& Co.). Cells were collected into tubes containing 1 ml of media, 
and a total of 1-5  x  10  s cells were collected into each tube. The 
cells were sorted into two fractions containing either CD45 +38- 
or CD38+45 -. The cells were then frozen in RPMI with 20% 
FCS and 10% DMSO. 
1024  Identification  of Cells Clonally  Related to Plasma Cell Tumor in Myeloma Figure 1.  PCR amplification  of 
the rearranged IgH locus  using  V, 
family-specific and J.  consensus 
oligonucleotide  primers.  (A) 
Schematic representation of  the 
events that occur during Ig heavy 
chain  gene rearrangement that 
create a genetically  unique  sequence 
that can be used as a marker of the 
disease.  Using  family-specific 
primers to the conserved  region of 
framework 1 and a J. consensus 
primer, the rearranged  allele(s) can 
be  amplified, sequenced, and an 
ASO can be generated  to the unique 
sequence.  (B)  Ethidium bro- 
mide-stained  polyacrylamide  gel of 
PCR  products derived from V. 
family-specific/J,  consensus  ampli- 
fication  of the rearranged Ig heavy 
chain  locus  from  seven  myeloma  BM 
samples. The band migrating at 
"~290 bp in all lanes is nonspecific. 
Preparation  of Whole-Ceil  Lysate  for RT-PCR.  Sorted  cells were 
washed twice with lx  PBS and then resuspended to give a final 
concentration of 14.5  x  104 cells//~l in lx  PBS. 1 #1 of tRNA 
at 0.5/~g/ml was added and then the cells were lysed at 95~  for 
10 min. To this, 2/~1 of proteinase K (Boehringer Mannheim Bio- 
chemical, Indianapolis, IN) at 10 mg/ml was added and incubated 
at 55~  for 30 min, followed by enzyme inactivation at 95~  for 
10 min. The sample was then centrifuged at full speed for 2 min 
and the supernatant was transferred to a new tube and stored at 
-80~  Approximately 10  s cells worth of lysate (7/~1) were used 
in the RT-ASO-PCR amplification  (see above). The only modifica- 
tion to the PCR amplification was that the ASO was end labeled 
with "y-[32p]dATP  using T4 polynucleotide  kinase as per supplier's 
protocol (New England Biolabs, Beverly,  MA), before  amplification. 
20 #1 of the final PCR product was separated on an 8% polyacryl- 
amide gel, dried, and exposed to x-ray film at room temperature 
for between  15 min and 5 h. 
Results 
PCR A mplification  of V-D-J Ig Heavy Chain Rearrangements 
in MM BM Samples.  The genetically unique sequence  en- 
compassing the V-D-J recombination junction (CDK3) has 
proven to be a useful tool in detecting and monitoring the 
presence  of B cell malignancies by ASO-PCR (20-24).  We 
isolated DNA and KNA from seven MM BM samples that 
had  been  previously characterized to  contain a  clonal V. 
rearrangement, expressed as either an a  or q/isotype. Within 
the marrow of these patients the tumor population constituted 
>45% of the total cellular content. As diagrammed in Fig. 
1 A, we used a pool of seven family-specific V. oligonucle- 
otides (29)  to framework 1 paired with a J. consensus oli- 
gonucleotide designed to the 5' portion of the JH region to 
amplify across  the  CDR3 junction  of these  MM  DNA 
samples. From six of the samples discrete amplified products 
derived from the predominant tumor cells could be detected 
by ethidium bromide staining after electrophoresis through 
a 6% polyacrylamide  gel (Fig. 1 B). The sizes of the amplified 
products range from 280 to 340 bp due to the heterogeneity 
in DH gene usage, nucleotide insertions, and deletions. Be- 
cause of the heterogeneity of the IgH gene rearrangements 
within the normal peripheral blood DNA sample, only a faint 
smear was observed.  A  nonspecific band of '~290 bp was 
amplified in all of the samples, and was not further charac- 
terized. Each of the DNA samples that produced an amplified 
product by V. family-specific PCR was then amplified with 
individual V. family oligonucleotides paired with the J, con- 
sensus oligonudeotide (or J4 in the case of M45) to deter- 
mine  which  V.  family gene  was  being  used  (data  not 
shown). The use of a single V. primer provided additional 
specificity  for subsequent PCR amplifications (see below). 
The  PCR-amplified  products  were  sequenced  and  the 
V-D-J boundaries were established based on previously pub- 
lished sequences  (30,  31) (see Fig. 3).  As previously shown 
(20,  21), the variety of nucleotide deletions and insertions 
between the coding  junctions, accompanied with the diverse 
use of D, and J. gene segments, generates a very unique se- 
quence and can provide a genetic marker of the clonal malig- 
nancy. ASOs were designed to each of the CDR3 with the 
5'-3' orientation toward the J, and C. segments (see Fig. 3). 
DNA ASO-PCR amplifications were performed on the six 
MM samples  as previously described (20,  21) to assess the 
specificity of the ASO. All of the samples produced a single, 
amplified product of the expected size and none of the ASOs 
were found to crossamplify any BM MM DNA for which 
it was not specific or normal peripheral blood DNA (data 
not shown). 
Detection of Clonally Related but Isotypically Distinct RNA 
Species by ASO RT-PCR.  Although myeloma is character- 
ized as a clonal proliferation of a plasma cell,  there is con- 
tinued debate over the presence  of earlier  lineage cells that 
are clonally related to the malignancy, and that may repre- 
sent clonal precursors.  The MM samples characterized in this 
study expressed  either C3' or Co~ heavy chain Ig, as deter- 
mined by isotype-specific  antibodies (not shown). We rea- 
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cation of  CH#, 6, % and ol reverse- 
transcribed  tumor  RNA.  (A) 
Depiction of an  KNA  molecule 
from the rearranged heavy  chain Ig 
gene. The  experimental method 
used to  detect RNA  transcripts 
bearing different constant region 
isotypes  that are clonally  related to 
the  myeloma  is  shown.  (B) 
Ethidium  bromide-stained poly- 
acrylamide  gel of two representative 
patient samples showing the exis- 
tence of different  isotype  RNA mol- 
ecules  that are clonally  related  to the 
tumor. The first lane in each  patient 
sample set denotes  the isotype  of the 
predominant tumor population. 
soned that if B cells earlier in development were present, they 
may express preswitch isotypes (C/z and C~5) and show clonal 
identity with  the plasma cell by virtue of the V-D-J junc- 
tional region. The tumor-specific ASO was used to examine 
this possibility.  The approach  taken is shown in Fig.  2 A. 
RNA from the patient marrow was reverse transcribed with 
one of several CHA primers  specific  for or, %  #,  or ~5 (see 
Table 1). Oligonucleotides Cy and Cot (both CHA and CHB) 
are consensus primers and recognize the four gene isoforms 
and  two  gene  isoforms,  respectively.  Addition  of the  V, 
family primer  that  corresponded  to the plasma cell tumor 
and PCR cycling with one of the CHA primers resulted in 
sdective amplification of a subset of RNA species  (i.e.,  iso- 
type and V. gene family restricted). A second round of PCR 
amplification was performed using the tumor-specific ASO 
paired  with  an  internal  C.  region primer  (CHB in  Fig.  2 
A  and Table 1). This amplification selectively amplified only 
cDNAs generated from the first amplification that contained 
the CDR3 identical to the plasma cell tumor. A representa- 
tive example of the RT-ASO-PCR products obtained from 
two of the patient  samples is shown in Fig.  2 B.  The first 
lane in each set shows the product of ASO paired with the 
C. expressed by the plasma cell tumor (M44-C3,; M45-Cot). 
The remaining lanes show products obtained by pairing the 
ASO with other isotype primers. Detection of the predomi- 
nant  RNA species derived from the plasma cell tumor re- 
Table  1.  Oligonucleotides Used in PCR  and R T 
Domain  + 
Oligo  Sequence  position 
J4  5'-GTGAGGACTCACCTGAGGAG-Y  J4 
C#A  5'-GGGTTGCCGAAGAAGCCGCCGCGGGGTGGG-y  CH2 
C#B  5'-GACGGAATTCTCACAGGAGAC-y  CH1 
C&A  5'-CCCAGTTATCAAGCATGCCAGGAC-y  CH1 
C~B  5'-TGGGTGTCTGCACCCTGATAT-y  CH1 
C~A  5'-TCT/cGAATTCAGGGT/cGCCAGGGGGAGAC-Y  CH1 
C~B  5'-GGGGAAGACCGATGGGCCCT-y  CH1 
C~A  5'-GGGATTCGTGTAGTGCTTCACGTG-Y  CH1 
C~B  5'-GAGGCTCAGCGGGAAGACCTT-3'  CH1 
255 
125 
139 
125 
121 
117 
209 
120 
* The amino acid number given designates the position of the 3' end of the oligo. All sequences  and position assignments 
(30, 42). 
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are as previously  reported quired only a single round of amplification. Thus, the inten- 
sity of the plasma cell RNA amplification product appears 
comparable to the other isotypes detected in the figure, but 
in fact actually represents the dominant spedes. Significantly, 
in all cases we demonstrated the existence of KNA species 
donally related to the plasma cell tumor, but associated with 
different isotypes. Based on the sequence of the original tumor 
CDR3, and the known location of each of the primers, we 
could precisely predict the sizes of the expected related PCR 
products. In each case, the size met the prediction. Our results 
demonstrate the presence of preswitch transcripts  (# and/~) 
that amplified with the tumor-specific  ASO. Interestingly, 
other clonally related isotypes could also be detected (c~ in 
3' tumor samples and 3' in o~ tumor samples). This result 
is not unexpected in light of previous reports demonstrating 
idiotypic identity between myeloma cells and other mature 
isotypes  (1). Similar results were obtained  from the RNA 
isolated from all six patients. 
Sequence Analyses of the Clonally Related RNAs Show Iden- 
tity in the CDR3 and Little Accumulation of  Additional Somatic 
Mutations after Switching.  To confirm the donal relationship 
of each of the PCR products obtained  from the myeloma 
samples, all of the products were sequenced (Fig. 3). The 
first line shown for each sample represents the sequence cor- 
responding to the predominant plasma cell malignancy. In 
each case the sequence of the other isotypes amplified with 
the tumor-specific ASO showed almost complete sequence 
identity in the CDR3, through the D and J gene segments, 
thus confirming the donal relationship. Differences  in sequence 
from published  germline sequences were noted in repeated 
sequence analyses, and presumably represent somatic muta- 
tions. These mutations were identical for a]] the isotypes within 
a single patient sample. Rare additional mutations were ob- 
served, two in the Ca transcript of M42, and one in the C3' 
transcript of M44. This demonstrates  a significant sequence 
stability after switch recombination, and suggests  somatic 
mutations do not accumulate during switch, in the absence 
of antigen selection (see Discussion). 
Distinct B Cell Populations Express the Transcripts Clonally 
Related to the Malignant Plasma Cell.  The antigenic CD cell 
v.a I  ~  I*  J'  *  II  CH  _ 
5"-...TGTGC CC~GGAI"TITTGGATrTGGGTTATCGGGTAC  TTC'I'I'rGACTAG~IGOTCACC~TCTOCTCA  GCCTCC/K3CAAOOOCCCA~ C~FA 
.......................................................  o~o~mOATCCao:ce-'~Aoccn'rrccccc~  .41~-~  CpO  I  ,so  ~--  .......................................................  ~arrce~e~[  _~coe 
.......................................................  aCA  "~  C~B 
v.,,I  ~  I  ,"  *  *  ￿9  *  II  c.  -  c  A 
M41  ~-...TOT~C O~OACMT~C.ACTACTrrcw3T  TOOTCCCc~'rOTCCTC~ -  ~  u  ---  "B 
I  ~o  ,~  - ..........................................................  aoaAa~c~:,x~'____.  ~l~'~'uF 
v  ...........................................................  ~TmTCCOCATO~B 
...........................................................  ~.~  ......  ~  CO~B 
v.,  I  Io.o-I  V  a,  .  .  .  II  c. 
8'-...TGTOC (~u~o.Acr'rc~'roooG  rr OACll~IO~O~J,~;,~c~'roxrcA'rC(STCTCCTCA ~  COf,  B 
I  -so  ~  ..............................................  o---c ............  a~o~~~'ql.~xCpB 
..............................................  o---c ............  ~TaTaTTCCCCATC~I---COB 
...............................................................  GCCTCC.~CCA  ~  a  C~ 
H  S'-..,TGT~ OAG(~3ATO~OTCATAI"IrG~TGATGAC'P3CTA13"C,  GGOAATGAAC  "I'rcoAGTCC~TGG~TCTCCTCA  ~  ~-.~O 
I  ,so  ~  ]]]]]]]]]]]]2]]]]]2]:[2]]]]]]]]]]]]2]]]]]~]]2]2  oo~oTaCA~~pe 
......................................................  QO:~.~CA  ~  C?e 
v."l  ~  I  .  J=  .  II  c. 
5"-...TGTGC (3iGGCG~IGCATCCATGACT~TGGOGT GcTrITGATATC~TGGTC,  ACCGTCTCTGCA  _  ~  C~A 
|  A$O  a~  " .............................................................  T--  ~  ---~---~CGCI"TTTCO~CCTC,~J~m~CpB 
v.,.  I  I....,I7  .  .,,  .  II  c. 
5'-..GGCCATATATTAI"rGTGC GAGAGATATTCCAT  TTCTT/~./~TC  GGCC/~GGAACCCT~TCACCGTC~ GCAI~_<<<=~_~~  CO~a 
.........................................................  aao~ta~  .....  4---~_CpB  I  ,,o  ~  ...........................................................  ~~~1"c~ 
...........................................................  ~x;g~.~. ~.a  ~;/ls 
Figure  3.  DNA sequence of the products  isolated from myeloma BM RNA that was reverse transcribed with the isotype-specific CH primers  and 
amplified using the tumor-specific  ASO. Sequence analyses of the RNA transcripts  are shown.  The initial  sequence shown for each patient sample 
denotes  the predominant tumor isotype.  Gene boundaries  are shown as boxed areas above the sequence with the gene segments  identified. The ASO 
is underlined  and the arrowhead  designates  the direction  of priming. The dashed lines represent  sequence identity among the RNA transcripts  and 
base changes  are indicated.  The isotype  primers  being used  to generate  the sequence are given on the right and  the sequence 5' of the primer are 
shown.  The open triangles  indicate deletions  and  the filled circles represent  somatic  mutations based on published  sequence information (30,  31). 
1027  Billadeau et al. Figure  4.  RT-ASO-PCR identification ofclonally related but isotype distinct RNA molecules in CD45/38 cell-sorted populations.  (.4) Cell popula- 
tions in the presort separation ofMM BM sample M41 as detected by CD45 and CD38 antibodies. Shown below the plot is an ethidium bromide-stained 
polyacrylamide gel of the products detected by ASO-RT-PCR using the isotype-specific primers for RT. The 6-amplified product could only be observed 
after reamplification of 5 #1 of the original  amplification.  (B) CD45 sort of M41 BM sample along with the autoradiogram  showing the isotypic 
clonally related RNA molecules detected within this population by RT-ASO-PCR. To detect the 8 transcript the film was exposed 20 times (C). Results 
from the CD38 sort of M41 BM sample along with the autoradiogram of the isotype-speeific  RNA detected within this sorted population by RT-ASO-PCR. 
surface markers are useful in separating populations of lym- 
phoid cells at different developmental stages.  Expression of 
two different isoforms of CD45 characterize normal B cell 
development. Expression of CD45RA occurs at all stages of 
pre-B and B cell development, whereas CD45RO occurs late 
after B cell activation. End-stage plasma cells lose all CD45 
expression (32). In contrast, CD38 is expressed in early pre-B 
and immature B cell stages, is lost during subsequent B cell 
differentiation, and then is expressed at high levels in end 
stage plasma cells (33, 34). The majority of MM tumor cells 
are CD38 +/CD45-.  Thus, separation of cells based on the 
expression of these two markers can yield distinct B cell popu- 
lations. 
Using FACS  |  analysis, the C~/-expressing  tumor M41 was 
found to express high levels of CD38 on its surface (Fig. 4). 
A two-color FACS  |  analysis using a PE-conjugated antibody 
against CD38 and a FITC-conjugated antibody that recog- 
nizes both isoforms of CD45 demonstrates a clear separation 
of CD38 +/CD45-  and  CD38-/CD45 +  cell populations 
(Fig.  4 A).  As seen before, RT-ASO-PCR  analysis  of the 
total, unsorted cell population shows the presence of all the 
clonaUy related but isotypically distinct RNA species (Fig. 
4 A,  bottom). The M41 marrow sample was then FACS  | 
sorted into the two distinct populations,  and each popula- 
tion was analyzed for the presence of the donally related tran- 
scripts  (Fig.  4, B  and C).  Yields of cells from the FACS  | 
sort were between 5  x  10  s and 1  x  106. To reduce the loss 
of RNA from these samples,  PCR  assays were performed 
on whole cell lysates (see Materials and Methods). Each PCR 
amplification was performed on lysate from ~o10  s cells.  In 
addition, sensitivity of detection was increased by end-labeling 
the  5'  end  of  the  ASO  primer  with  32p  before  the 
amplification. The PCR amplifications were carried out as 
described above, and the products were visualized by autora- 
diography after gel electrophoresis.  The results shown in Fig. 
4 B demonstrate that the C#,  C~, and Coe transcripts that 
amplify with the ASO are present in the CD38-/CD45 +- 
sorted population,  while the tumor-derived C3' transcript 
is  not.  In contrast,  the CD38+/CD45--sorted  cells  uni- 
quely express the C'y tumor transcript, but none of the other 
isotypes. The 20 x  exposed film does show a very faint band 
corresponding to an amplified C~ transcript in the CD38-/ 
CD45 +-sorted population, although amplified/~, 8, and c~ 
transcripts are not observed in the CD38+/CD45--sorted 
population (data not shown). The observation of the C3' tran- 
script  in  the CD45 +  population  may have resulted from 
contaminating CD38 + cells in the CD45 + pool or it may 
represent  a  transition  cell  phenotype  (CD38 +/CD45 +). 
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clonally related to the tumor population, but isotypically dis- 
tinct,  are derived from a population of cells separate from 
the terminally differentiated plasma cell tumor. 
Discussion 
A number of reports have suggested the existence of ear- 
lier B lineage cells that are clonally related to the plasma cell 
tumor population in myeloma patients (1-14). Some reports 
have demonstrated the presence of B cells in the peripheral 
blood of MM patients that share the same IgH gene rear- 
rangements (5-7). However, there has been no direct evidence 
that these cells represent clonally related preswitch popula- 
tions,  distinct from the plasma cell. Earlier B lineage cells 
have been shown to be present that express Ig idiotypically 
related to the plasma cell tumor; however, antiidiotypic anti- 
bodies have been shown to crossreact with normal peripheral 
blood cells. Finally, it has recently been reported that in the 
PBL of MM patients there exists a monoclonal population 
of B lymphocytes that express late-stage B cell differentia- 
tion CD markers (32), but there was no evidence that these 
populations were clonaUy related to the plasma cell tumor 
in the marrow. In this report we have demonstrated the pres- 
ence of Ig/~ and Ig/~ transcripts that are clearly clonally related 
to the terminally differentiated plasma cell tumor (expressing 
Ig3' or Igor). This clonal relationship was confirmed by ap- 
plication of a tumor-specific RT-ASO-PCR technique, and 
verified by sequence analysis of the different isotype-associated 
transcripts in the unique CDR3 of the IgH locus. Our results 
are in agreement with a previous abstract report (35) in which 
/~ transcripts were found to be amplified with primers specific 
to the terminally differentiated myeloma population. 
In previous reports we have estimated the percentages of 
tumor-related cells in both the marrow (20) and peripheral 
blood (21) using a DNA-based PCR assay. In this report we 
have used an RNA-based PCR assay. We can conclude that 
the preswitch transcripts comprise a very small percentage 
of the total tumor-related R.NA, based on the fact that an 
additional 30-40 cycles of PCR were required to detect the 
preswitch  isotypes.  However,  because  this  extensive 
amplification is well beyond the linear range of PCR,  ac- 
curate estimates of relative transcript levels are not possible. 
Moreover, the relative levels of related RNA transcripts are 
certainly dependent on rates  of transcription,  which vary 
significantly among B cell and plasma cell populations. Thus, 
a quantitative comparison of related, but isotypic distinct, 
RNA  transcripts  would  have  no  bearing  on  actual  cell 
numbers. 
An additional observation we made was that there was a 
lack of significant accumulation of somatic mutations, when 
comparing the/z and ~ sequences with the switched plasma 
cell 3' or c~ sequences. From the six patients analyzed we noted 
only three nucleotide differences in the CDR3s  sequenced. 
The most commonly accepted mechanism for isotype switch 
is by the switch recombination of V-D-J  to a downstream 
heavy chain constant region. Switched heavy chain alleles fre- 
quently accrue a significant amount of somatic mutations 
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during the normal immune response due to continued anti- 
genic stimulation and selection. The lack of accumulating 
somatic mutations from the preswitch to the postswitch iso- 
type observed in our study suggests that the donal prolifera- 
tion and differentiation of the tumor occurs in the absence 
of antigen stimulation and sdection. A  similar observation 
was noted in a cell line that was programmed to switch in 
vitro without antigenic stimulation (36). 
Due to the sequence identity observed within the clonaUy 
related  transcripts  and  the  recent  observation  of an  IgG 
paraproteinaemia that simultaneously expressed cytoplasmic 
IgM and IgG (37), we wanted to rule out the possibility that 
the expression of clonally related isotypes we were observing 
was derived from a single call population.  It was possible 
that the distinct isotype transcripts we observed were the re- 
sult of differential splicing of large transcripts,  as has been 
observed in some mouse B cells (38), or trans-splicing  (39) 
from a single population of cells. By sorting the cells based 
on cell surface expression of CD38 and CD45, we demon- 
strated that the clonal g  and 8 transcripts were being made 
in a cell compartment distinct from the plasma cell tumor. 
The expression of CD38 is of a discontinuous nature; it is 
found early in B cell development, lost on mature and acti- 
vated B cells, and reexpressed on almost all mydoma plasma 
cells (34). CD45 expression also occurs early in B cell devel- 
opment,  through  activated  B  cells  (RA  subgroup)  and 
preplasma cells (RO subgroup), but is lost on plasma cells 
(32). Our results from sorted populations of one patient show 
that the clonally related transcripts were derived from dis- 
tinct populations. Because the cells expressing the clonally 
related  #  and  /~  transcripts  were  found  in  the  CD38-/ 
CD45 § population, this suggests these transcripts were de- 
rived from a mature B cell phenotype. Ira myeloma precursor 
population is present, it would seem likely that the cell would 
have already progressed through heavy and light chain rear- 
rangements before the transforming event, otherwise clonal 
rearrangements with identical CDR3s would be required to 
obtain the clonal plasma cell population found in the marrow. 
However, because the plasma cell tumor is generally expressing 
a predominant switched isotype, a precursor model would 
require that g-expressing cells undergo a dominant switch 
recombination to produce the donal isotype observed. In- 
deed,  programmed  switching of murine B  cells has been 
documented (40). 
Although the plasma cell tumors in these patients show 
a clonal isotype, we did find evidence for donally related cells 
that express different switch isotypes, likely from other switch 
recombinations (i.e., we could detect clonally related c~ ex- 
pression in predominantly 3' myelomas, and 3' expression in 
cr myelomas). This would suggest that even if switch is pro- 
grammed,  other  minor  switch  recombinations  do  occur. 
Previous reports  showing programmed switches have also 
noted other minor switch isotypes (40).  Interestingly, Ve- 
sole et al.  (41)  have found that in a significant percentage 
of relapsing myeloma patients who had received autologous 
bone marrow transplants, relapses expressed different isotypes. 
They suggest that their therapeutic strategies may provide 
a selective advantage to new populations of clonally related cells. Our observations would serve to explain these results. 
It there is a preswitched progenitor population, clonal out- 
growths of new isotypes may be possible The clonal rela- 
tionship of initial and relapse cell populations could be ad- 
dressed by the RT-ASO-PCR approach we described in this 
report. 
Our analysis was confined to BM populations derived from 
banked samples of newly diagnosed myeloma patients.  We 
did not have access to peripheral blood samples; however, this 
should be an important future consideration in light of studies 
that demonstrate monoclonal populations of late-stage B cells 
in PBL of MM patients (32). As described in a previous re- 
port (21), we found by ASO-PCR analysis of PBL DNA that 
in some MM patients there was a significant number of cells 
clonally related to the plasma cell tumor, despite the fact there 
were no detectable clonal plasma cells in the PBL. Finally, 
Bergui et al. (8) have reported an IL-3- and IL-6-dependent 
proliferation and differentiation of malignant precursors from 
PBL of MM patients  to plasma cells in vitro.  All of these 
observations lend support to the presence of precursor popu- 
lations, and strongly suggest the peripheral blood should be 
carefully examined. 
Additional studies will be required to further characterize 
the preswitch population of cells we have identified, and their 
potential to influence the course of the disease. The clonally 
related # cell population cannot be assumed to be transformed 
solely on the evidence that it is related to the plasma cell tumor. 
Subsequent studies should address this issue and help eluci- 
date the true malignant stage in multiple myeloma. In addi- 
tion, new protocols in the treatment of myeloma include the 
use of purged autologous marrow or marrow reconstitution 
with peripheral blood stem cells.  Our results highlight  the 
need to identify and characterize clonally related cells whose 
presence may influence the outcome of these therapeutic ap- 
proaches. 
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